CN102202661A - 降低循环氧化低密度脂蛋白-β-2-糖蛋白1复合物以治疗动脉粥样硬化的方法 - Google Patents

降低循环氧化低密度脂蛋白-β-2-糖蛋白1复合物以治疗动脉粥样硬化的方法 Download PDF

Info

Publication number
CN102202661A
CN102202661A CN2009801442637A CN200980144263A CN102202661A CN 102202661 A CN102202661 A CN 102202661A CN 2009801442637 A CN2009801442637 A CN 2009801442637A CN 200980144263 A CN200980144263 A CN 200980144263A CN 102202661 A CN102202661 A CN 102202661A
Authority
CN
China
Prior art keywords
oil
oxldl
circulating
dietary
fatty acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801442637A
Other languages
English (en)
Chinese (zh)
Inventor
博米·P·弗莱姆罗兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102202661A publication Critical patent/CN102202661A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2009801442637A 2008-11-14 2009-11-10 降低循环氧化低密度脂蛋白-β-2-糖蛋白1复合物以治疗动脉粥样硬化的方法 Pending CN102202661A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11482308P 2008-11-14 2008-11-14
US61/114,823 2008-11-14
PCT/IB2009/007669 WO2010055419A2 (en) 2008-11-14 2009-11-10 A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis

Publications (1)

Publication Number Publication Date
CN102202661A true CN102202661A (zh) 2011-09-28

Family

ID=42170470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801442637A Pending CN102202661A (zh) 2008-11-14 2009-11-10 降低循环氧化低密度脂蛋白-β-2-糖蛋白1复合物以治疗动脉粥样硬化的方法

Country Status (11)

Country Link
US (1) US9446013B2 (https=)
EP (1) EP2355812B1 (https=)
JP (2) JP2012508791A (https=)
KR (1) KR20110098909A (https=)
CN (1) CN102202661A (https=)
AU (1) AU2009315314B2 (https=)
BR (1) BRPI0915247A2 (https=)
CA (1) CA2743434C (https=)
DK (1) DK2355812T3 (https=)
MX (1) MX2011005077A (https=)
WO (1) WO2010055419A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
NO344004B1 (en) * 2017-06-23 2019-08-12 Olivita As Combination of oils
US20220403442A1 (en) * 2019-10-21 2022-12-22 President And Fellows Of Harvard College Compositions and methods for detection of oxidizable analytes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665496A (zh) * 2002-05-03 2005-09-07 派普生物保健品公司 Epa和dha在二级预防神经性疾患,特别是中风中的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
GB2238476A (en) * 1989-11-04 1991-06-05 K T Lalvani Therapeutic aquatic animal and garlic products
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
DE19855426A1 (de) * 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
JP2001346517A (ja) * 2000-06-02 2001-12-18 K-Tac Planners Co Ltd 食用油脂。
DE20105126U1 (de) * 2001-03-23 2002-01-31 Bartz, Volker, 35440 Linden Fischöl zur oralen Einnahme
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
ES2254018B2 (es) * 2004-11-16 2009-01-01 Universidad Autonoma De Madrid Mezcla oleosa de ingredientes bioactivos naturales para la preparacion de un producto alimenticio enriquecido.
US20100144878A1 (en) * 2005-04-29 2010-06-10 Popp Michael A Nutritional supplement or functional food comprising oil combination
US20090252853A1 (en) * 2005-11-30 2009-10-08 Angel Gil Hernandez Lipid Mixture and Use Thereof in the Preparation of a Product That Is Intended for Enteral or Oral Administration
DK1800675T3 (da) * 2005-12-23 2011-09-05 Nutricia Nv Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
JP5099808B2 (ja) * 2006-05-29 2012-12-19 独立行政法人農業・食品産業技術総合研究機構 脂質代謝改善用組成物
EP2083622A4 (en) * 2006-10-18 2009-12-09 Reliant Pharmaceuticals Inc METHODS OF USING OMEGA-3 FATTY ACIDS TO REDUCE LP-PLA2 RATES
US20090270502A1 (en) * 2007-01-11 2009-10-29 Carotino Sdn. Bhd. Method for Lowering Risk of Cardiovascular Diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665496A (zh) * 2002-05-03 2005-09-07 派普生物保健品公司 Epa和dha在二级预防神经性疾患,特别是中风中的用途

Also Published As

Publication number Publication date
JP2012508791A (ja) 2012-04-12
BRPI0915247A2 (pt) 2016-02-16
DK2355812T3 (da) 2019-10-07
WO2010055419A2 (en) 2010-05-20
EP2355812A2 (en) 2011-08-17
CA2743434A1 (en) 2010-05-20
KR20110098909A (ko) 2011-09-02
US20110207821A1 (en) 2011-08-25
AU2009315314B2 (en) 2013-04-18
CA2743434C (en) 2015-04-21
US9446013B2 (en) 2016-09-20
EP2355812A4 (en) 2012-04-18
JP2015091855A (ja) 2015-05-14
MX2011005077A (es) 2011-05-25
WO2010055419A3 (en) 2010-09-10
AU2009315314A1 (en) 2010-05-20
EP2355812B1 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
Harris et al. Stearidonic acid-enriched soybean oil increased the omega-3 index, an emerging cardiovascular risk marker
AU2010201897B2 (en) Dietary supplement composition for blood lipid health
TW202027737A (zh) 用於治療或預防由暴露於空氣污染導致之疾病及/或病症之組合物及方法
US8507466B2 (en) Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
Chiu et al. The regulatory effects of fish oil and chitosan on hepatic lipogenic signals in high-fat diet-induced obese rats
CN108096235A (zh) 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20150250757A1 (en) Methods for treating hypertriglyceridemia
CN102202661A (zh) 降低循环氧化低密度脂蛋白-β-2-糖蛋白1复合物以治疗动脉粥样硬化的方法
AU2004210244C1 (en) Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides
Fard et al. Comparison of the bioavailability of docosapentaenoic acid (DPA, 22: 5n-3) and eicosapentaenoic acid (EPA, 20: 5n-3) in the rat
Aguila et al. Effects of chronic high fat diets on renal function and cortical structure in rats
Skoczyńska et al. Linseed oil increases HDL3 cholesterol and decreases blood pressure in patients diagnosed with mild hypercholesterolaemia
Khan et al. Thermally oxidized olive oil oroduces biochemical, physiological effects and fatty liver in rats
HK1158526A (en) A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
Zhu et al. Different postprandial metabolic patterns after the consumption of fish oil and lard in healthy Chinese individuals
Choudhury et al. Exploring the Role of Omega-6/Omega-3 Ratio in Disease Management: Insights from Dietary Impact and Molecular Docking Analyses
Afdhal et al. Omega-3 for Inflammatory Bowel Disease: Is it worthy?-A
Veselinovic et al. Clinical Benefits of n-3 PUFA and PUFA and ɤ-Linolenic A-Linolenic Acid in Patients with Rheumatoid Arthritis
US20150258050A1 (en) Method for reducing triglycerides
HK1086168B (en) Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1158526

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110928

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1158526

Country of ref document: HK